Generic Name and Formulations:
Esomeprazole (as sodium) 20mg, 40mg; per vial; pwd for IV inj after reconstitution or for infusion after reconstitution and dilution.
Company:
AstraZeneca Pharmaceuticals
Short-term (up to 10 days) alternative to oral therapy for GERD with erosive esophagitis.
Inject IV over ≥ 3 minutes or infuse IV over 10–30 minutes. ≥18yrs: 20–40mg once daily for ≤10 days; switch to oral form when feasible. Severe hepatic impairment: max 20mg/day.
Infuse IV over 10–30 minutes. <1month: not recommended. 1month–<1yr: 0.5mg/kg. 1yr–17yrs: <55kg: 10mg; ≥55kg: 20mg.
Proton pump inhibitor.
Long term and multiple daily dose therapy: increased risk of osteoporosis-related fractures. Monitor magnesium levels with long-term therapy. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant atazanavir, nelfinavir: not recommended. May potentiate saquinavir; monitor and consider reducing saquinavir dose. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron salts, digoxin). Antagonizes clopidogrel; consider alternative anti-platelet therapy. May affect drugs metabolized by CYP2C19. Avoid concomitant with St. John's Wort, rifampin. May potentiate tacrolimus, cilostazol (consider reduced dose), methotrexate (consider temporary withdrawal of PPI). Monitor warfarin. May give antacids concomitantly. May cause false (+) results in diagnostic investigations for neuroendocrine tumors.
Headache, diarrhea, abdominal pain, nausea, flatulence, constipation, dry mouth, inj site reactions; rare: rash, allergic reactions, hypomagnesemia, possible C. difficile associated diarrhea. Children: Also, somnolence, regurgitation, tachypnea, increased ALT.
See Biaxin for more information on clarithromycin. See Amoxil for more information on amoxicillin.
Hepatic (CYP2C19, CYP3A4). 97% protein bound.
Renal (primarily), fecal.
NO
Caps—30, 90, 1000; Susp—30 packets/box; IV soln (single-use vial)—10